The phrase "assay potency" is correct and usable in written English.
It is typically used in scientific or pharmaceutical contexts to refer to the measurement of the strength or effectiveness of a substance, often a drug or chemical.
Example: "The laboratory conducted an assay potency test to determine the effectiveness of the new medication."
Alternatives: "measure efficacy" or "test strength".
This study has led to the discovery of novel inhibitors whose profiles include activity against TACE in an enzyme assay, potency in the suppression of LPS-stimulated TNF-α in human whole blood, selectivity against a panel of MMPs and oral bioavailability.
13 The results of the sporozoite membrane integrity (viability) and 6-day hepatocyte potency assay (potency) were similar to those for the previous trials (Supplemental Table 1).
The in vitro assay potency results fell within twofold of the potency seen ex vivo in human whole blood, for two reference compounds with reported clinical data, targeting the same pathway.
For each slice, distance from the origin (center) is proportional to the normalized value (e.g., assay potency or predicted bioavailability) of the component data points composing that slice, and the width (in radians) indicates the relative weight of that slice in the overall ToxPi calculation.
For quantitative assays, potencies of samples 2, 3, and 4 were estimated relative to sample 1 by using parallel-line analysis of log-transformed data.
The Bzm modification on ShhN imparted a significant increase in activity as assessed in the C3H10T1/2 functional assay with potency comparable to that of the endogenous dual-lipidated form of ShhN (ShhNp).
As in the primary assay, the potency assay format yielded highly robust data (Z′=0.80±0.08; Table 2).
Within any single assay, the potency of the active compounds (based on AC50 values) varied as much as five orders of magnitude.
Notably in this assay, the potency of ranibizumab for blocking 20 pM VEGF-A121 or VEGF-A165 induced luciferase activity through VEGFR1 was only slightly greater than that of bevacizumab.
It is not clear the degree to which the in vitro assay of potency actually reflects the in vivo activity, and the efficacy and low toxicity shown in the orthotopic model suggests these compounds could prove useful clinically.
A second BET inhibitor based on a different chemotype, PFI-1 [ 18, 24], reduced t½ to levels similar to that of the double-mutant, confirming in the FRAP assay the potency observed in vitro against both bromodomains.
